Clinical Manifestations and Genetic Profile of Chinese Patients with NK-Cell Large Granular Lymphocytic Leukemia—A Single-Center Retrospective Analysis
International Journal of Molecular Sciences · 13.07.2026 · 27 (14) · 6227
DOI: 10.3390/ijms27146227 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.07.2026. Verfasst von Zhe Zhuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, No. 1 Shuaifu Yuan, Beijing 100032, China. Hauptthemen laut MEDLINE: Leukemia, Large Granular Lymphocytic, Killer Cells, Natural. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences (ClFMS), Capital's Funds for Health Improvement and Research, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Natural killer cell large granular lymphocytic leukemia (NK-LGLL) is a rare and heterogenous lymphoproliferative disorder. This study retrospectively evaluated 35 consecutive Chinese patients (median age 58 years) to evaluate their unique clinical–biological profiles and treatment responses. Our Chinese population exhibited a distinct comorbidity spectrum, characterized by a lower prevalence of concurrent arthritis (2.9%) and secondary malignancies, compared with Western cohorts. At diagnosis, 31.4% of the cohort had neutropenia, 42.9% had anemia, and 31.4% had thrombocytopenia. The median large granular lymphocyte count was 3.9 × 109/L (range 0.11–114.8 × 109/L; IQR 1.9 × 109/L, 5.9 × 109/L). Immunophenotyping consistently identified as a CD3- CD56+ clone. Notably, genomic profiling via NGS revealed a STAT3 mutation rate of 14.3%. Regarding therapeutic efficacy, frontline immunosuppressive therapy with cyclophosphamide or cyclosporine was associated with favorable clinical responses (best overall response, complete remission rate 66.7% for both). Additionally, sirolimus emerged as a potentially highly effective salvage option, yielding an overall response rate of 85.7% (95%CI 42.1–99.6%) and complete remission rate of 57.1%. With an estimated 3-year overall survival rate of 85.6% (95%CI 73.3%, 99.8%), our findings suggest a generally indolent clinical course of NK-LGLL in this Chinese cohort and highlight the potential of mTOR inhibition in refractory cases, warranting further prospective investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, No. 1 Shuaifu Yuan, Beijing 100032, China.
- Department of Internal Medicine, Peking Union Medical College Hospital, No. 1 Shuaifu Yuan, Beijing 100032, China.
ORCID-Profile: Zhe Zhuang
Förderung
- CAMS Innovation Fund for Medical Sciences (ClFMS)
- Capital's Funds for Health Improvement and Research
- National High Level Hospital Clinical Research Funding
- Peking Union Medical College Hospital Talent Cultivation Program
Zitieren
APA
Zhuang, Z., Zhu, H., Chen, C., Di, Y., He, Z., Zhang, W., Zhou, D., & Zhang, Y. (2026). Clinical Manifestations and Genetic Profile of Chinese Patients with NK-Cell Large Granular Lymphocytic Leukemia—A Single-Center Retrospective Analysis. International Journal of Molecular Sciences, 27(14), 6227. https://doi.org/10.3390/ijms27146227
Vancouver
Zhuang Z, Zhu H, Chen C, Di Y, He Z, Zhang W, et al. Clinical Manifestations and Genetic Profile of Chinese Patients with NK-Cell Large Granular Lymphocytic Leukemia—A Single-Center Retrospective Analysis. International Journal of Molecular Sciences. 2026;27(14):6227. doi:10.3390/ijms27146227
BibTeX
@article{Zhuang2026,
author = {Zhuang, Zhe and Zhu, Huiying and Chen, Chao and Di, Yiao and He, Zhangyuting and Zhang, Wei and Zhou, Daobin and Zhang, Yan},
title = {Clinical Manifestations and Genetic Profile of Chinese Patients with NK-Cell Large Granular Lymphocytic Leukemia—A Single-Center Retrospective Analysis},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6227},
doi = {10.3390/ijms27146227}
}
EUVIMED